Implementing	O
Non-Invasive	O
Prenatal	B:C0033053
Diagnosis	I:C0033053
(	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
)	O
in	O
a	O
National	O
Health	I:C0022877
Service	I:C0022877
Laboratory	I:C0022877
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	O
.	O

Implementing	O
Non-Invasive	O
Prenatal	O
Diagnosis	I:C0033053
(	O
Non-Invasive	B:C0033053
Prenatal	I:C0033053
Diagnosis	I:C0033053
)	O
in	O
a	O
National	O
Health	I:C0022877
Service	I:C0022877
Laboratory	I:C0022877
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	O
.	O

Implementing	O
Non-Invasive	O
Prenatal	O
Diagnosis	I:C0033053
(	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
)	O
in	O
a	O
National	B:C0022877
Health	I:C0022877
Service	I:C0022877
Laboratory	I:C0022877
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	O
.	O

Implementing	O
Non-Invasive	O
Prenatal	O
Diagnosis	I:C0033053
(	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
)	O
in	O
a	O
National	O
Health	I:C0022877
Service	I:C0022877
Laboratory	I:C0022877
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	B:C0012634
.	O

Our	O
UK	B:C0022877
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	O
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	I:C0039743
,	O
Apert	O
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Our	O
UK	O
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	B:C0033053
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	O
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	I:C0039743
,	O
Apert	O
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Our	O
UK	O
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	B:C0443147
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	I:C0039743
,	O
Apert	O
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Our	O
UK	O
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	O
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	B:C0001080
,	O
thanataphoric	O
dysplasia	I:C0039743
,	O
Apert	O
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Our	O
UK	O
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	O
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	B:C0039743
dysplasia	I:C0039743
,	O
Apert	O
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Our	O
UK	O
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	O
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	I:C0039743
,	O
Apert	B:C0001193
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Our	O
UK	O
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	O
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	I:C0039743
,	O
Apert	O
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	B:C0026882
exclusion	O
for	O
cystic	O
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Our	O
UK	O
National	I:C0022877
Health	I:C0022877
Service	I:C0022877
regional	I:C0022877
genetics	I:C0022877
laboratory	I:C0022877
offers	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
for	O
autosomal	O
dominant	I:C0443147
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	I:C0039743
,	O
Apert	O
syndrome	I:C0001193
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	B:C0010674
fibrosis	I:C0010674
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

Non-Invasive	B:C0033053
Prenatal	I:C0033053
Diagnosis	I:C0033053
avoids	O
the	O
risks	O
associated	O
with	O
invasive	O
testing	I:C0430022
,	O
making	O
prenatal	O
diagnosis	I:C0033053
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O

Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
avoids	O
the	O
risks	B:C0035648
associated	O
with	O
invasive	O
testing	I:C0430022
,	O
making	O
prenatal	O
diagnosis	I:C0033053
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O

Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
avoids	O
the	O
risks	O
associated	O
with	O
invasive	B:C0430022
testing	I:C0430022
,	O
making	O
prenatal	O
diagnosis	I:C0033053
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O

Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
avoids	O
the	O
risks	O
associated	O
with	O
invasive	O
testing	I:C0430022
,	O
making	O
prenatal	B:C0033053
diagnosis	I:C0033053
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	B:C0011900
for	O
autosomal	O
recessive	I:C0265388
diseases	I:C0265388
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	O
in	O
the	O
cell	O
-	I:C4289789
free	I:C4289789
DNA	I:C4289789
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	O
for	O
autosomal	B:C0265388
recessive	I:C0265388
diseases	I:C0265388
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	O
in	O
the	O
cell	O
-	I:C4289789
free	I:C4289789
DNA	I:C4289789
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	O
for	O
autosomal	O
recessive	I:C0265388
diseases	I:C0265388
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	B:C0596988
allele	O
in	O
the	O
cell	O
-	I:C4289789
free	I:C4289789
DNA	I:C4289789
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	O
for	O
autosomal	O
recessive	I:C0265388
diseases	I:C0265388
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	B:C0002085
in	O
the	O
cell	O
-	I:C4289789
free	I:C4289789
DNA	I:C4289789
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	O
for	O
autosomal	O
recessive	I:C0265388
diseases	I:C0265388
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	O
in	O
the	O
cell	B:C4289789
-	I:C4289789
free	I:C4289789
DNA	I:C4289789
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	O
for	O
autosomal	O
recessive	I:C0265388
diseases	I:C0265388
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	O
in	O
the	O
cell	O
-	I:C4289789
free	I:C4289789
DNA	I:C4289789
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	B:C0449445
.	O

Validation	B:C1519941
and	O
diagnostic	O
implementation	O
for	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
of	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
(	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
Non-Invasive	B:C0033053
Prenatal	I:C0033053
Diagnosis	I:C0033053
of	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
(	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
of	O
congenital	B:C0001627
adrenal	I:C0001627
hyperplasia	I:C0001627
(	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
of	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
(	O
congenital	B:C0001627
adrenal	I:C0001627
hyperplasia	I:C0001627
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
of	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
(	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
)	O
is	O
further	O
complicated	O
by	O
presence	B:C0150312
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
of	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
(	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	B:C0033799
that	O
requires	O
a	O
different	O
approach	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
of	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
(	O
congenital	O
adrenal	I:C0001627
hyperplasia	I:C0001627
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	B:C0449445
.	O

We	O
have	O
used	O
an	O
assay	B:C0005507
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	I:C1413861
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	O
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	B:C0752046
around	O
the	O
CAH	O
gene	I:C1413861
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	O
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	B:C1413861
gene	I:C1413861
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	O
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	I:C1413861
(	O
CYP21A2	B:C1413861
)	O
to	O
construct	O
the	O
high	O
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	I:C1413861
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	I:C1413861
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	O
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	B:C0449445
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	I:C1413861
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	O
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	B:C0002085
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	I:C1413861
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	O
-	I:C0332167
risk	I:C0332167
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
Non-Invasive	B:C0033053
Prenatal	I:C0033053
Diagnosis	I:C0033053
.	O

We	O
are	O
evaluating	O
various	O
measures	O
of	O
the	O
fetal	B:C0015965
fraction	O
to	O
help	O
determine	O
inheritance	O
of	O
parental	O
mutations	O
.	O

We	O
are	O
evaluating	O
various	O
measures	O
of	O
the	O
fetal	O
fraction	O
to	O
help	O
determine	O
inheritance	O
of	O
parental	O
mutations	B:C0026882
.	O

We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
Non-Invasive	B:C0033053
Prenatal	I:C0033053
Diagnosis	I:C0033053
multi-	O
disorder	I:C0022885
panel	I:C0022885
for	O
autosomal	O
recessive	I:C0265388
disease	I:C0265388
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	O
conditions	I:C0019247
.	O

We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
multi-	B:C0022885
disorder	I:C0022885
panel	I:C0022885
for	O
autosomal	O
recessive	I:C0265388
disease	I:C0265388
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	O
conditions	I:C0019247
.	O

We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
multi-	O
disorder	I:C0022885
panel	I:C0022885
for	O
autosomal	B:C0265388
recessive	I:C0265388
disease	I:C0265388
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	O
conditions	I:C0019247
.	O

We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
Non-Invasive	O
Prenatal	I:C0033053
Diagnosis	I:C0033053
multi-	O
disorder	I:C0022885
panel	I:C0022885
for	O
autosomal	O
recessive	I:C0265388
disease	I:C0265388
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	B:C0019247
conditions	I:C0019247
.	O

